# Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Canonical URL: https://biopharmsignal.com/news/ZURA/zura-bio-reports-first-quarter-2026-financial-results-and-recent-corporate-updates
Ticker: ZURA
Company: Zura Bio
Source: Zura Bio
Published: 2026-05-07 11:30 EST
Original Source URL: https://investors.zurabio.com
## Summary

Continuing advancement of two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) (TibuSHIELD) and systemic sclerosis (SSc) (TibuSURE), with both trials on track to meet anticipated timelines Strengthened leadership team with key executive and Board appointments Completed an

## Article Body
Continuing advancement of two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) (TibuSHIELD) and systemic sclerosis (SSc) (TibuSURE), with both trials on track to meet anticipated timelines Strengthened leadership team with key executive and Board appointments Completed an
## Recent Company News
- 2026-05-13 11:30 EST — [Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer](https://biopharmsignal.com/news/ZURA/zura-bio-expands-leadership-team-with-appointment-of-muzammil-mustufa-as-chief-business-officer) — Source: Zura Bio
- 2026-05-07 11:30 EST — [Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates](https://biopharmsignal.com/news/ZURA/zura-bio-reports-first-quarter-2026-financial-results-and-recent-corporate-updates) — Source: Zura Bio
- 2026-05-04 20:05 EST — [Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ZURA/zura-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Zura Bio
- 2026-03-19 20:05 EST — [Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates](https://biopharmsignal.com/news/ZURA/zura-bio-reports-full-year-2025-financial-results-and-recent-corporate-updates) — Source: Zura Bio
- 2026-03-05 11:30 EST — [Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress](https://biopharmsignal.com/news/ZURA/zura-bio-to-present-phase-2-tibusure-study-design-poster-evaluating-dual-il-17a-and-baff-inhibition-in-systemic-sclerosis-at-9th-systemic-sclerosis-world-congress) — Source: Zura Bio
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)